Hepatitis C management in post-transplant patients

Area of Science:

• Hepatology
• Virology
• Transplantation Medicine

Background:

• Hepatitis C virus (HCV)-related cirrhosis is a primary indication for liver transplantation (LT).
• Recurrence of HCV post-LT is nearly universal and accelerates fibrosis, leading to graft failure and increased mortality.
• Effective management of HCV in post-transplant patients is critical.

Purpose of the Study:

• To review recent advancements in treating Hepatitis C virus (HCV) in patients who have undergone liver transplantation (LT).
• To highlight the efficacy of new direct-acting antiviral (DAA) therapies for HCV recurrence post-LT.
• To provide an updated perspective on managing this challenging complication.

Main Methods:

• Review of recent clinical data and studies on HCV treatment in post-LT patients.
• Analysis of treatment outcomes, including sustained virologic response (SVR), with various antiviral regimens.
• Focus on the role and efficacy of direct-acting antivirals (DAAs).

Main Results:

• Traditional interferon-based therapies showed limited efficacy and were often used off-label in this population.
• Direct-acting antivirals (DAAs) demonstrate promising results for achieving sustained virologic response (SVR) in HCV post-LT.
• DAAs represent a significant improvement over previous treatment options for HCV recurrence.

Conclusions:

• HCV recurrence post-liver transplantation necessitates vigilant monitoring and prompt treatment.
• Direct-acting antivirals (DAAs) have revolutionized HCV treatment in post-transplant patients, offering better outcomes.
• Continued research and clinical application of DAAs are essential for improving long-term graft and patient survival.